CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.160
-0.160 (-6.90%)
Jun 23, 2025, 4:00 PM - Market closed
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 5, which predicts a 131.48% increase from the current stock price of 2.16.
Price Target: $5 (+131.48%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 20, 2025.
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +131.48% | May 20, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $2.5 → $5 | Buy | Maintains | $2.5 → $5 | +131.48% | May 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +131.48% | May 15, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $3.25 → $2.5 | Buy | Maintains | $3.25 → $2.5 | +15.74% | Apr 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 7, 2025 |
Financial Forecast
Revenue This Year
80.41M
from 138.10M
Decreased by -41.77%
Revenue Next Year
45.87M
from 80.41M
Decreased by -42.96%
EPS This Year
0.02
from 0.38
Decreased by -95.74%
EPS Next Year
-0.48
from 0.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 92.8M | 126.0M | 52.5M | ||
| Avg | 80.4M | 45.9M | 18.2M | ||
| Low | 61.7M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -32.8% | 56.7% | 14.5% | ||
| Avg | -41.8% | -43.0% | -60.3% | ||
| Low | -55.4% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.29 | 0.15 | -0.53 | ||
| Avg | 0.02 | -0.48 | -0.65 | ||
| Low | -0.43 | -0.69 | -0.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -23.5% | 815.0% | - | ||
| Avg | -95.7% | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.